Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from dorsaVi Limited ( (AU:DVL) ) is now available.
dorsaVi Limited has begun developing Sensor V6.5, a major firmware upgrade that adds on-sensor intelligence and neuromorphic-ready architecture to its existing wearable sensor platform. The update shifts more analytics and signal processing directly onto the device, cutting latency and enabling faster, more responsive applications in clinical, workplace, sporting and research environments.
Because V6.5 is delivered via firmware, current customers, including Select Medical’s physical therapy network, an elite sports program and the SEROMA European clinical study, can gain enhanced capabilities without replacing hardware. The upgrade lays the groundwork for dorsaVi’s planned Ultra-Edge Platform 1.0, supports future ultra-low-power intelligent sensing across sectors such as robotics and human-machine systems, and aligns with regulatory trends favoring validated on-device AI processing.
The most recent analyst rating on (AU:DVL) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on dorsaVi Limited stock, see the AU:DVL Stock Forecast page.
More about dorsaVi Limited
dorsaVi Limited is an Australian medical technology company that develops FDA- and TGA-cleared wearable sensors for measuring human movement in clinical, workplace and elite sports settings. Its systems provide high-fidelity motion data and validated movement metrics to clients such as physical therapy networks, sports programs and clinical research studies, with a growing focus on real-time analytics and reduced cloud dependence.
Average Trading Volume: 1,051,590
Technical Sentiment Signal: Sell
Current Market Cap: A$32.67M
For an in-depth examination of DVL stock, go to TipRanks’ Overview page.